Frances Oldham Kelsey: The Pharmacologist Who Stopped Thalidomide

Frances Kathleen Oldham Kelsey (July 24, 1914 – August 7, 2015) was a Canadian-American pharmacologist and physician who spent 45 years with the U.S. Food and Drug Administration. She refused to authorize thalidomide for market, a decision that prevented thousands of birth defects when the drug was later shown to cause severe fetal harm.

Early Life and Education

Kelsey was born in Cobble Hill, British Columbia. She attended St. Margaret’s School in Victoria, graduating at age 15, then spent a year at Victoria College (now University of Victoria) from 1930 to 1931. She enrolled at McGill University, where she earned a B.Sc. in pharmacology in 1934 and an M.Sc. in 1935.

A professor encouraged her to contact E.M.K. Geiling, a noted researcher establishing a new pharmacology department at the University of Chicago. Geiling, unaware of the spelling conventions between Francis and Frances, addressed his offer to “Mr. Oldham.” Kelsey accepted while correcting the error by writing “miss” in brackets on her reply. She began her graduate work in 1936.

During her second year, Geiling was retained by the FDA to investigate unusual deaths linked to elixir sulfanilamide. Kelsey assisted on this research, which identified diethylene glycol as the poisonous solvent responsible for 107 deaths. The incident exposed gaps in drug regulation; Congress responded by passing the Federal Food, Drug, and Cosmetic Act of 1938. That same year, Kelsey completed her Ph.D. in pharmacology, becoming the first woman to earn a doctorate in the field. Her work with Geiling sparked her interest in teratogens—drugs that cause birth defects—and the mechanisms by which they operate.

Career and Achievements

After completing her Ph.D., Kelsey joined the University of Chicago faculty. In 1942, she conducted research on synthetic antimalarial compounds, work that revealed how certain drugs cross the placental barrier. She met fellow faculty member Fremont Ellis Kelsey during this period and married him in 1943.

While teaching at Chicago, Kelsey earned her M.D. in 1950 and worked as an editorial associate for the American Medical Association Journal for two years. In 1954, she left the university to teach pharmacology at the University of South Dakota in Vermillion, where she remained until 1957. She became a dual Canadian-American citizen in the 1950s to continue practicing medicine in the United States, though she maintained close ties to Canada and visited her siblings regularly throughout her life.

In 1960, the FDA hired Kelsey in Washington, D.C. She was one of only seven full-time and four part-time physicians reviewing drugs for the agency at that time.

Notable Events and Milestones

One of Kelsey’s first assignments was reviewing Richardson-Merrell’s application to market thalidomide (tradename Kevadon) as a tranquilizer and painkiller for pregnant women with morning sickness. Although the drug had been approved in Canada and over 20 European and African countries, Kelsey withheld approval and requested clinical trial data. The FDA could only withhold approval for 60 days at a time, so she repeatedly requested additional information from the company over more than a year.

Kelsey found the company’s testimonials lacking scientific rigor and recognized their authors as having published questionable articles previously. She also noted that the application contained no information about the drug’s chirality. In December 1960, Leslie Florence published a letter in the British Medical Journal linking thalidomide to neurological symptoms. Kelsey incorporated Florence’s findings into her data requests and, recalling her earlier research on birth defect mechanisms, demanded animal studies to prove the drug would not harm the fetus.

Richardson-Merrell had discovered birth defects in rat testing but did not disclose this; instead, they provided misleading partial data suggesting safety for pregnant women. Despite thalidomide’s widespread use abroad, Kelsey remained skeptical and scrutinized the evidence carefully, sometimes asking her husband to verify her conclusions. Her superiors at the FDA supported her position even as Richardson-Merrell’s contact pressed for faster approval. In November 1961, births of deformed infants in Europe were linked to maternal thalidomide use during pregnancy, vindicating Kelsey’s caution.

Awards and Honors

In 1962, President John F. Kennedy awarded Kelsey the President’s Award for Distinguished Federal Civilian Service. She was the second woman to receive this honor.

Additional Resources

Kelsey’s story remains central to discussions of drug safety regulation and the FDA’s role in protecting public health. Her work on thalidomide led directly to stronger pharmaceutical oversight laws. More detailed information about her life and career is available through Wikipedia and other biographical archives documenting twentieth-century medical history.

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn